Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Altor BioScience begins development of ALT-803 for multiple myeloma

Nov. 5, 2014

arGEN-X files IND to begin study of ARGX-110 in Waldenstrom's macroglobulinemia

Nov. 4, 2014

Glioma candidate pritumumab receives U.S. orphan drug designation

Nov. 3, 2014

Kurume University discloses new cancer antigen peptide vaccines

Oct. 29, 2014

Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG

Oct. 28, 2014

Medivation licenses anti-PD-1 antibody pidilizumab from CureTech

Oct. 24, 2014

EMA grants orphan drug designation to isactuzumab govitecan

Oct. 21, 2014

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Oct. 16, 2014

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

Oct. 16, 2014

Phase I data for MPDL-3280A for the treatment of UBC and other malignancies

Oct. 15, 2014

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...